# Thymic carcinoma

Source: https://onco.cc/cancers/thymic-carcinoma/  
OnCo record `thymic-carcinoma` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Thymic carcinoma is the aggressive kind of thymic epithelial tumour, a cancer of the thymus that behaves like carcinoma elsewhere and has often spread when found. Surgery is attempted when possible, carboplatin with paclitaxel is the usual chemotherapy, and sunitinib, lenvatinib and the PD-1 antibody pembrolizumab have shown responses in trials, with lenvatinib approved in Japan.

## Summary

Thymic carcinoma differs from thymoma in every way that matters: its cells are overtly malignant, it lacks the immature T lymphocytes and the organotypic features of thymoma, it is rarely associated with myasthenia gravis, and it presents with local invasion, pleural spread or distant metastases in most patients. Squamous cell carcinoma is the commonest subtype, followed by lymphoepithelioma-like, basaloid, mucoepidermoid, sarcomatoid and NUT carcinoma (covered on its own page); thymic neuroendocrine carcinomas are classified separately. KIT mutations occur in about a tenth of thymic carcinomas, mostly squamous, and respond to imatinib in case series, and TP53, CDKN2A and epigenetic regulator mutations are common; PD-L1 is often highly expressed.

Complete resection is attempted for localised disease, followed by postoperative radiotherapy, and chemotherapy is given before surgery for borderline tumours. For advanced disease the guidelines favour carboplatin and paclitaxel, which produced responses in about a fifth of patients with thymic carcinoma in prospective series, with CAP or platinum-etoposide as alternatives. After platinum, three phase 2 trials define the options: sunitinib (Lancet Oncology 2015) produced responses in about a quarter of 23 patients with thymic carcinoma; lenvatinib in the Japanese REMORA trial (Lancet Oncology 2020) produced responses in 38 percent of 42 patients and was approved in Japan in 2021; and pembrolizumab (Lancet Oncology 2018) produced responses in 22.5 percent of 40 patients with durable benefit but severe immune-related adverse events, including myocarditis, in 15 percent, a rate high enough that PD-1 antibodies are used only with monitoring and are avoided in thymoma. Newer agents in trials include the multikinase inhibitor KC1036, the TROP2 antibody-drug conjugate sacituzumab tirumotecan, ramucirumab with carboplatin and paclitaxel, and CAR-NK cells against CD30 or mesothelin.

## Fields

- Kind: Cancer
- Last checked: 2026-09-18
- Also known as: Thymic squamous cell carcinoma; Type C thymoma (obsolete); Thymic carcinoma; Malignant thymic epithelial tumour
- Tags: subtype-page; thoracic
- Group: thoracic
- Burden: About a fifth of thymic epithelial tumours; usually found at an advanced stage with invasion of the mediastinum or spread to pleura, nodes and distant organs, and rarely tied to myasthenia gravis.
- Subtypes: Thymic squamous cell carcinoma (the commonest form; KIT mutations in a subset); Lymphoepithelioma-like thymic carcinoma (EBV-associated in some); Basaloid, mucoepidermoid and adenocarcinoma of the thymus; Sarcomatoid thymic carcinoma; Resectable thymic carcinoma (surgery and postoperative radiotherapy); Advanced or metastatic thymic carcinoma (carboplatin-paclitaxel, then kinase inhibitors or pembrolizumab)
- Biomarkers: Histological subtype and CD5, CD117 (KIT) and p63 immunohistochemistry; TNM and Masaoka-Koga stage; Completeness of resection; KIT mutation (imatinib-responsive subset); PD-L1 expression (high in many; not required for pembrolizumab); Baseline troponin and autoimmune screen before PD-1 therapy

## Sections of this record

The page is a hub with ten sections in reading order; large sections have their own page. The same plan as JSON: https://onco.cc/api/v1/cancers/thymic-carcinoma/sections.json

- Overview (on the hub): The TL;DR, the family this cancer belongs to, the organ, who gets it and what the state of the art is. https://onco.cc/cancers/thymic-carcinoma/#overview [3 state-of-the-art points]
- Types and stages (on the hub): Anatomy, the subtypes and how they differ, how it is staged, and where advanced disease spreads. https://onco.cc/cancers/thymic-carcinoma/#what-it-is [6 subtypes]
- Symptoms and diagnosis (on the hub): How this cancer shows itself, how the diagnosis is confirmed, and the biomarkers clinicians test for. https://onco.cc/cancers/thymic-carcinoma/#finding-it [6 biomarkers]
- Treatment (on the hub): The standard of care by setting, the medicines, surgery and radiotherapy named in it, and the regimens behind them. https://onco.cc/cancers/thymic-carcinoma/#treating-it [5 settings, 5 decisions with options]
- Trials and papers (on the hub): Trials recruiting now, the landmark trials, the trials held by this cancer's subtypes, the key papers and what they mean, the latest literature, and the milestones year by year. https://onco.cc/cancers/thymic-carcinoma/#evidence [3 trials, 4 key papers, 6 milestones]
- Biology and targets (on the hub): The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models. https://onco.cc/cancers/thymic-carcinoma/#science [8 targets]
- Countries and centres (own page): Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes. https://onco.cc/cancers/thymic-carcinoma/where-you-are/
- Decisions and support (on the hub): The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask. https://onco.cc/cancers/thymic-carcinoma/#living-with-it [19 questions, 6 red cards]
- Pipeline and open problems (own page): Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record. https://onco.cc/cancers/thymic-carcinoma/coming/ [12 medicines, 3 trials, 4 open problems]
- Data (own page): Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked. https://onco.cc/cancers/thymic-carcinoma/data/ [50 connected records]

## Standard of care

- Resectable disease: Complete resection with thymectomy and involved structures; postoperative radiotherapy for all stages of thymic carcinoma; chemotherapy considered after incomplete resection. ([Robotic & minimally invasive surgery](https://onco.cc/technologies/robotic-surgery/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Proton therapy](https://onco.cc/technologies/proton-therapy/))
- Borderline resectable: Induction chemotherapy (carboplatin-paclitaxel or CAP) followed by surgery or radiotherapy according to response. ([Carboplatin](https://onco.cc/drugs/carboplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/))
- Advanced, first line: Carboplatin and paclitaxel; CAP or platinum-etoposide as alternatives. ([Carboplatin](https://onco.cc/drugs/carboplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/))
- After platinum: Sunitinib; lenvatinib (approved in Japan, REMORA); pembrolizumab with cardiac and autoimmune monitoring; everolimus; imatinib for KIT-mutant tumours. ([Sunitinib](https://onco.cc/drugs/sunitinib/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Everolimus](https://onco.cc/drugs/everolimus/), [Imatinib](https://onco.cc/drugs/imatinib/), [Immune-related adverse events (irAEs)](https://onco.cc/terms/irae/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/))
- Trials: KC1036, sacituzumab tirumotecan, CAR-NK cells, ramucirumab combinations. ([A Study of KC1036 in Patients with Advanced Thymic Tumors](https://onco.cc/trials/nct05683886/), [Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma](https://onco.cc/trials/nct07324629/), [Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma](https://onco.cc/trials/nct07598955/), [KC1036](https://onco.cc/drugs/kc1036/), [EB-CAR30-NK](https://onco.cc/drugs/eb-car30-nk/))

## State of the art

- Carboplatin and paclitaxel is the accepted first-line regimen on prospective phase 2 evidence.
- Lenvatinib is the first drug approved anywhere specifically for thymic carcinoma.
- Pembrolizumab gives durable responses in a fifth of patients but at a real risk of myocarditis.

## Open problems

- No randomised trial has compared any two regimens in thymic carcinoma.
- The sequence of kinase inhibitors and immunotherapy is unstudied.
- Predicting which patients will develop myocarditis on PD-1 antibodies is not yet possible.
- Long-term survival in metastatic disease remains poor.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Thymic_carcinoma
- REMORA lenvatinib (Lancet Oncology 2020): https://doi.org/10.1016/S1470-2045(20)30162-5
- Pembrolizumab in thymic carcinoma (Lancet Oncology 2018): https://doi.org/10.1016/S1470-2045(18)30062-7
- Wikipedia: https://en.wikipedia.org/wiki/Thymic_carcinoma

## Connected records

- cancers: [Extrapulmonary neuroendocrine carcinoma](https://onco.cc/cancers/extrapulmonary-nec/), [Thymoma (WHO types A, AB, B1, B2 and B3)](https://onco.cc/cancers/thymoma/), [Thymoma and thymic carcinoma](https://onco.cc/cancers/thymic-epithelial/), [Type B3 thymoma](https://onco.cc/cancers/thymoma-type-b3/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Proton therapy](https://onco.cc/technologies/proton-therapy/), [Robotic & minimally invasive surgery](https://onco.cc/technologies/robotic-surgery/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [KIT](https://onco.cc/targets/kit/), [PD-1](https://onco.cc/targets/pd1/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [EB-CAR30-NK](https://onco.cc/drugs/eb-car30-nk/), [Everolimus](https://onco.cc/drugs/everolimus/), [Imatinib](https://onco.cc/drugs/imatinib/), [KC1036](https://onco.cc/drugs/kc1036/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Sunitinib](https://onco.cc/drugs/sunitinib/)
- terms: [Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC)](https://onco.cc/terms/staging-systems/), [Immune-related adverse events (irAEs)](https://onco.cc/terms/irae/), [Tumour mutational burden (TMB)](https://onco.cc/terms/tmb/)
- trials: [A Study of KC1036 in Patients with Advanced Thymic Tumors](https://onco.cc/trials/nct05683886/), [Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma](https://onco.cc/trials/nct07324629/), [Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma](https://onco.cc/trials/nct07598955/)
- key papers: [Pembrolizumab in patients with thymic carcinoma: a single-arm phase 2 study](https://onco.cc/key-papers/paper-giaccone-pembrolizumab-thymic-carcinoma-lancet-oncol-2018/), [REMORA: lenvatinib in advanced or metastatic thymic carcinoma](https://onco.cc/key-papers/paper-remora-lenvatinib-thymic-carcinoma-lancet-oncol-2020/), [The 2021 WHO classification of tumours of the thymus and mediastinum: what is new in thymic epithelial, germ cell and mesenchymal tumours](https://onco.cc/key-papers/paper-who-2021-thymus-mediastinum-classification-marx-jto-2022/), [Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-esmo-thymic-epithelial-tumours-guideline-ann-oncol-2015/)

---
JSON: https://onco.cc/api/v1/entities/thymic-carcinoma.json